HK Stock Market Move | ASCLETIS-B(01672) rose more than 4%, the company's oral dual-target compound makes another move, expected to further expand the value of the ASC30 platform.

ASCLETIS-B (01672) rose more than 4%, rising 3.79% to HK$8.76 as of the time of writing, with a turnover of HK$1045.03 million. On the news front, ASCLETIS-B recently announced that it has selected ASC48, a potential first-in-class oral small molecule GIPR agonist, and a fixed dose combination formulation of ASC30, an oral small molecule GLP-1R agonist, for clinical development. The fixed dose combination formulation of ASC30 and ASC48 (ASC30_48 FDC) simultaneously targets GLP-1R and GIPR, offering a potential first-in-class "once daily, once a day" oral therapy for obesity. In non-human primate studies, this combination therapy resulted in a weight loss of 10.5% over 8 days, an increase of approximately 52% compared to ASC30 alone. It is expected to submit an IND to the US FDA in Q4 2026. The company believes that this combination therapy has the potential to balance oral convenience with dual-target efficacy, further expanding the platform value of ASC30. The company has currently developed a multi-level weight loss pipeline of "oral small molecules + super long-acting injectable peptides" and "single drug + fixed dose combination", with the potential to gradually transition from a single core product-driven approach to a multi-pipeline and platform-driven strategy in the future.